“Spesolimab Increases the Percentage of Generalized Pustular Psoriasis (GPP) Patients With Clear Skin over Time As Measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 Trial”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s490. https://doi.org/10.25251/skin.8.supp.490.